This site is intended for healthcare professionals


Select the drug indication to add to your list

Breast cancer
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:


Generic Name and Formulations:
Ado-trastuzumab emtansine 100mg, 160mg; per vial; powder; for IV infusion after reconstitution.

Genentech, Inc.

Therapeutic Use:

Indications for KADCYLA:

Treatment in patients with HER2-positive (+), metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy.


Give by IV infusion only over 90 minutes 3.6mg/kg max every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. Subsequent infusions may be given over 30 minutes if previously tolerated. Monitor closely for possible SC infiltration during infusion. Dose modifications: see full labeling.


Not established.


Do not substitute for or with trastuzumab. Hepatotoxicity; monitor serum transaminases and bilirubin prior to starting and to each dose; reduce dose or discontinue if occurs. Permanently discontinue if serum transaminases >3XULN and with total bilirubin >2XULN. Risk of left ventricular dysfunction. Assess LVEF prior to initiation and every 3 months during treatment; interrupt and discontinue as appropriate. Embryo-fetal toxicity: verify pregnancy status prior to initiation. Permanently discontinue if interstitial lung disease or pneumonitis occurs. Monitor for signs/symptoms of extravasation, infusion-related or hypersensitivity reactions; if significant, slow or interrupt infusion; discontinue if life-threatening. Monitor platelets at baseline and prior to each dose; if platelets <50,000/mm3, delay dose until recovery to ≥75,000/mm3; if platelets <25,000/mm3, delay until recovery to ≥75,000/mm3 and reduce dose. If thrombocytopenia occurs <100,000/mm3 and concomitant anticoagulants, monitor closely. Monitor for neurotoxicity; withhold temporarily if Grade 3 or 4 peripheral neuropathy occurs. Test for HER2 protein overexpression or gene amplification using FDA-approved tests by labs with demonstrated proficiency. Pregnancy: avoid. Use effective contraception during therapy and for 7 months (females) or 4 months (males) after last dose. Nursing mothers: not recommended (during and for 7 months after last dose).


Avoid concomitant strong CYP3A4 inhibitors (eg, azole antifungals, clarithromycin, atazanavir, indinavir, ritonavir, nefazodone, nelfinavir, saquinavir, telithromycin); if unavoidable, consider delaying therapy. Caution with concomitant anticoagulation or antiplatelet therapy; monitor closely.

Pharmacological Class:

HER2-targeted antibody-drug conjugate.

Adverse Reactions:

Fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache; increased transaminases, constipation, epistaxis, oligohydramnios (do fetal testing if occurs), infertility.


Enroll pregnant women who were exposed to Kadcyla in the MotHER Pregnancy Registry (800) 690-6720.

Generic Availability:


How Supplied:

Single-use vial—1

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.

Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Groin swelling - red flag symptomsExternal web site

This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...

0.50 Credits
Red flags

Erectile dysfunction - red flag symptomsExternal web site

This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...

0.50 Credits
Red flags

Headache - red flag symptomsExternal web site

Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Basal cell carcinoma: clinical reviewExternal web site

In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...

1.50 Credits
Clinical Review

Cardiomyopathy: clinical reviewExternal web site

This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...

1.50 Credits
Clinical Review

Parkinson's disease: clinical reviewExternal web site

Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »